|Bid||68.00 x 800|
|Ask||76.78 x 1400|
|Day's Range||73.08 - 75.31|
|52 Week Range||47.75 - 84.37|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.36|
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.
These stocks are heavily owned by high-turnover hedge funds, and thus are likely to face severe selling pressure once these funds turn bearish.
Seattle Genetics, Inc.'s (NASDAQ:SGEN): Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. On 31 December 2018, theRead More...
Seattle Genetics, Inc. announced today that management will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 10:40 a.m.
Commercial real estate investors are seeking out opportunities in places like Bothell where prices are lower relative to much of the rest of the Eastside.
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS to include ADCETRIS in combination with AVD in adults patients with previously untreated CD30+ stage IV classical Hodgkin lymphoma .
Seattle Genetics stock toppled Friday after the biotech met expectations for fourth-quarter sales of cancer treatment Adcetris, but issued soft 2019 guidance for its only approved drug.
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...
Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SGEN totaled $1.34 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -46.15% and 5.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Bothell, Washington-based company said it had a loss of 75 cents. Losses, adjusted for one-time gains and costs, came to 57 cents per share. The results missed Wall Street expectations. ...
-ADCETRIS® Net Sales in U.S. and Canada of $476.9 Million in 2018, Including $132.1 Million in the Fourth Quarter-
Seattle Genetics, Inc. announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m.